2024
Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis
Chintoh A, Liu L, Braun A, Akseer S, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, McGlashan T, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis. Schizophrenia Research 2024, 271: 153-160. PMID: 39029145, DOI: 10.1016/j.schres.2024.07.030.Peer-Reviewed Original ResearchClinical high riskClinical high-risk individualsSex differencesNegative symptomsTransition to psychosisInvestigate sex differencesNo sex differencesSchizophreniform disorderCHR individualsPsychosisSubstance useSchizophreniaSymptomsHigh riskIndividualsSchizophreniformAnxietyClinical presentationSexDepressionDisordersBaselineDifferencesMaleYouthRobust Brain Correlates of Cognitive Performance in Psychosis and its Prodrome
Ward H, Beermann A, Xie J, Yildiz G, Felix K, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Coleman M, Bouix S, Holt D, Öngür D, Breier A, Shenton M, Heckers S, Halko M, Lewandowski K, Brady R. Robust Brain Correlates of Cognitive Performance in Psychosis and its Prodrome. Biological Psychiatry 2024 PMID: 39032726, DOI: 10.1016/j.biopsych.2024.07.012.Peer-Reviewed Original ResearchAuditory continuous performance taskConnectome-wide association studiesEarly psychosisCognitive performanceNorth American Prodrome Longitudinal Study 2At-risk individualsCorrelates of cognitive performanceBrain-cognition relationshipsBrain-phenotype relationshipsBrain-behavior associationsContinuous performance taskEarly-course psychosisLongitudinal Study 2Resting-state fMRIProspective study of individualsHuman Connectome ProjectPsychosis onsetStudy of individualsPsychosisStudy 2Performance tasksNeurocognitive impairmentCognitive instrumentsHealthy participantsRobust associationsNeurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning
Carrión R, Ku B, Dorvil S, Auther A, McLaughlin D, Addington J, Bearden C, Cadenhead K, Cannon T, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Walker E, Woods S, Cornblatt B. Neurocognition in adolescents and young adults at clinical high risk for psychosis: Predictive stability for social and role functioning. Schizophrenia Research 2024, 271: 129-137. PMID: 39024961, DOI: 10.1016/j.schres.2024.06.054.Peer-Reviewed Original ResearchClinical high riskCHR-PNeurocognitive deficitsImpact of processing speedProcessing speedNorth American Prodrome Longitudinal StudyBaseline processing speedCHR-P participantsPoor social functioningCHR-P individualsYoung adultsDisorganized symptomsBaseline neurocognitionAttentional impairmentAttention deficitDevelopmental trajectoriesNeurocognitionPsychosisImpact of symptomsProdromal phaseSocial functioningIntervention issuesTreatment targetLongitudinal studyDeficitsThe Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program
Ferrara M, Basaldella M, Vacca F, Woods S, Walsh B, Cannon T, Srihari V, Grassi L. The Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program. Early Intervention In Psychiatry 2024 PMID: 38769052, DOI: 10.1111/eip.13548.Peer-Reviewed Original ResearchClinical high riskFirst-episode psychosisDSM-5-Attenuated Psychosis SyndromeItalian adaptationPsychosis syndromeDSM-5FEP programsEarly stages of psychosisItalian versionFirst-episode psychosis servicesFull-blown psychosisStages of psychosisEpisode of psychosisClinical structured interviewEpisode psychosisEstablished psychosisTrained psychologistsPsychiatric historyPsychosisPsychosis servicesHigh riskStructured interviewsClinical settingEarly detection of individualsAssess validityLongitudinal Trajectories of Premorbid Social and Academic Adjustment in Youth at Clinical High Risk for Psychosis: Implications for Conversion
Cowan H, Mittal V, Addington J, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Woods S, Cannon T, Walker E. Longitudinal Trajectories of Premorbid Social and Academic Adjustment in Youth at Clinical High Risk for Psychosis: Implications for Conversion. Schizophrenia Bulletin 2024, sbae050. PMID: 38706103, DOI: 10.1093/schbul/sbae050.Peer-Reviewed Original ResearchConversion to psychosisClinical high riskAcademic adjustmentPremorbid periodPremorbid adjustmentNegative symptomsNon-convertersSocial adjustmentLongitudinal trajectoriesChildhood trauma impactsPremorbid adjustment trajectoriesPremorbid social functioningPoor academic adjustmentBetween-person levelPsychotic disorder diagnosisNon-affective psychosisPoor social adjustmentGrowth curve modelsPsychotic disordersPremorbid functioningChildhood traumaDisorder diagnosisCognitive effectsPsychosisAdjustment problemsThe Hierarchical Taxonomy of Psychopathology in Clinical High Risk for Psychosis: Validation and Extension
Williams T, Williams A, Cowan H, Walker E, Cannon T, Bearden C, Keshavan M, Cornblatt B, Addington J, Woods S, Perkins D, Mathalon D, Cadenhead K, Stone W, Mittal V. The Hierarchical Taxonomy of Psychopathology in Clinical High Risk for Psychosis: Validation and Extension. Journal Of Psychopathology And Clinical Science 2024, 133: 235-244. PMID: 38546628, PMCID: PMC11273326, DOI: 10.1037/abn0000893.Peer-Reviewed Original ResearchConceptsHierarchical Taxonomy of PsychopathologyTaxonomy of PsychopathologyClinical high riskHiTOP modelCHR-PChildhood traumaDimensional models of psychopathologyHierarchical taxonomyModels of psychopathologyAttenuated psychotic symptomsBipolar spectrum disordersObsessive-compulsive disorderCHR-P individualsConfirmatory factor analysisPsychotic symptomsPsychotic disordersComorbid diagnosesHiTOPSpectrum disorderPsychosisPsychopathologySocial functioningSelf-reportSpecific hypothesesTest specific hypothesesPlasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Byrne J, Healy C, Föcking M, Heurich M, Susai S, Mongan D, Wynne K, Kodosaki E, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, Jeffries C, Perkins D, Cotter D. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain Behavior And Immunity 2024, 119: 188-196. PMID: 38555993, DOI: 10.1016/j.bbi.2024.03.049.Peer-Reviewed Original ResearchNegative symptomsDepressive symptomsScale of Psychosis-risk SymptomsMeasures of negative symptomsNorth American Prodrome Longitudinal Study 2Psychosis-risk symptomsClinical high riskPrognostic factorsLongitudinal Study 2Positive symptomsNAPLS 2Psychotic disordersAntipsychotic usePsychotic experiencesCannabis useSuicidal ideationAntidepressant useStudy 2Regulation groupQuality of life of individualsGroup factorsCurrent treatment optionsDemographic prognostic factorsPsychosisCoagulation proteinsAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needsDifferential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich M, Cagney G, Wynne K, Bearden C, Woods S, Cornblatt B, Mathalon D, Stone W, Cannon T, Addington J, Cadenhead K, Perkins D, Jeffries C, Cotter D. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain Behavior And Immunity 2024, 117: 175-180. PMID: 38219978, DOI: 10.1016/j.bbi.2023.12.018.Peer-Reviewed Original ResearchGlobal Assessment of Functioning ScaleNorth American Prodrome Longitudinal StudyClinical high riskPoor functionScale of Psychosis-risk SymptomsPsychosis-risk symptomsAssociated with poorer functioningFirst-episode psychosisTransition to psychosisGreater symptom severityFollow-upIndividuals at-riskClinical symptomsPsychotic disordersHigh riskSymptom severityPsychosocial functioningGlobal functioningPsychosisSubscale scoresFDR correctionAcute phase inflammatory responseLongitudinal studyGlobal assessmentFunctional scales
2014
Current status specifiers for patients at clinical high risk for psychosis
Woods SW, Walsh BC, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH. Current status specifiers for patients at clinical high risk for psychosis. Schizophrenia Research 2014, 158: 69-75. PMID: 25012147, PMCID: PMC4152558, DOI: 10.1016/j.schres.2014.06.022.Peer-Reviewed Original ResearchConceptsNorth American Prodromal Longitudinal StudyClinical high-risk syndromeHigh-risk syndromeCurrent clinical statusPsychosis risk syndromeLongitudinal studyClinical high riskPartial remissionFull remissionClinical statusRemission criteriaRisk syndromeProgression criteriaRole functioningPredictive validityHigh riskRemitted patientsRemissionPatientsCurrent statusSyndromeConvergent validityPsychosisStructured interviewsPresent study